Corey Davis
Stock Analyst at HC Wainwright & Co.
(3.00)
# 1,463
Out of 4,981 analysts
17
Total ratings
75%
Success rate
25.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $48.68 | +701.15% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $1.12 | +4,364.29% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $19.76 | +102.43% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $2.98 | +5,613.52% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $4.51 | +343.46% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $27.12 | +84.37% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $126.16 | +14.14% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $48.68
Upside: +701.15%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $1.12
Upside: +4,364.29%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $19.76
Upside: +102.43%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $2.98
Upside: +5,613.52%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $4.51
Upside: +343.46%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $27.12
Upside: +84.37%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $126.16
Upside: +14.14%